Eesti - eesti - Ravimiamet

tasmanian alkaloids pty. ltd. - oripaviin - pulber - 950g 1tk

Eesti - eesti - Ravimiamet

tasmanian alkaloids pty. ltd. - tebaiin - pulber - 500g 1tk

Eesti - eesti - Ravimiamet

alkaloid - int d.o.o. - kaltsiumkarbonaat+magneesiumkarbonaat - närimistablett - 680mg+80mg 16tk; 680mg+80mg 24tk; 680mg+80mg 96tk; 680mg+80mg 48tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Eesti - eesti - Ravimiamet

alkaloid a/o - verapamiil - süstelahus - 2,5mg 1ml 2ml 10tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - asitromütsiin - kõvakapsel - 250mg 6tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 20mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 40mg 1ml 30ml 1tk; 40mg 1ml 15ml 1tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - asitromütsiin - õhukese polümeerikattega tablett - 500mg 3tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - vinblastiin - süstelahus - 1mg 1ml 10ml 1tk